Durable Survival and Enhanced Downstaging: Long-term Insights from the NEOpredict-Lung Trial on Preoperative PD-1 and LAG-3 Blockade

Durable Survival and Enhanced Downstaging: Long-term Insights from the NEOpredict-Lung Trial on Preoperative PD-1 and LAG-3 Blockade

Extended follow-up of the NEOpredict-Lung trial demonstrates that short-course preoperative nivolumab, with or without relatlimab, yields high 3-year survival rates and significant nodal downstaging in resectable NSCLC, positioning dual checkpoint inhibition as a potent chemotherapy-free neoadjuvant alternative.
Tumor Treating Fields Significantly Delay Intracranial Progression in NSCLC Patients Following Stereotactic Radiosurgery: Results of the METIS Trial

Tumor Treating Fields Significantly Delay Intracranial Progression in NSCLC Patients Following Stereotactic Radiosurgery: Results of the METIS Trial

The Phase 3 METIS trial demonstrates that Tumor Treating Fields (TTFields) following stereotactic radiosurgery significantly prolongs time to intracranial progression in NSCLC patients with brain metastases, without compromising neurocognitive function or quality of life, offering a promising new treatment paradigm.
Combined Fascial Plane Blocks Fail to Superiorize Paravertebral Block in Mastectomy: Results from a 1,507-Patient Cluster-Randomized Trial

Combined Fascial Plane Blocks Fail to Superiorize Paravertebral Block in Mastectomy: Results from a 1,507-Patient Cluster-Randomized Trial

A large-scale cluster-randomized trial involving 1,507 patients demonstrated that adding PECS I blocks to paravertebral or serratus anterior plane blocks does not reduce postoperative opioid use or improve recovery compared to paravertebral block alone in mastectomy with reconstruction.
Survival Proportional Odds Outperforms Cox Regression in High-Heterogeneity Heart Failure Trials: Insights from DAPA-HF and DELIVER

Survival Proportional Odds Outperforms Cox Regression in High-Heterogeneity Heart Failure Trials: Insights from DAPA-HF and DELIVER

A critical reanalysis of the DAPA-HF and DELIVER trials reveals that the survival proportional odds model provides greater statistical power and more robust treatment effect estimates than traditional Cox regression in heart failure populations characterized by high risk heterogeneity.
Precision Medicine in Atrial Fibrillation: Biomarker-Based ABC-AF Risk Scores Fail to Outperform Standard Care

Precision Medicine in Atrial Fibrillation: Biomarker-Based ABC-AF Risk Scores Fail to Outperform Standard Care

A large-scale registry-based RCT reveals that tailoring atrial fibrillation treatment using the biomarker-driven ABC-AF risk score does not significantly reduce stroke or death compared to current standard guideline-based care, highlighting the complexities of implementing precision medicine in clinical practice.